<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110811">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730365</url>
  </required_header>
  <id_info>
    <org_study_id>NL40578.031.12</org_study_id>
    <nct_id>NCT01730365</nct_id>
  </id_info>
  <brief_title>Optical Detection of Malignancy During Percutaneous Interventions</brief_title>
  <official_title>Discrimination of Benign and Malignant Human Tissue During Percutaneous Interventions Using Optical Spectroscopy Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Healthcare</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of application possibilities of optical spectroscopy within the field of
      oncology. Optical spectroscopy enables the possibility to specifically differentiate between
      different (human) tissues. The hypothesis is that incorporation of this technique into
      existing medical devices (e.g. biopsy needle) would enlarge the accuracy and reliability of
      these devices. The purpose is to improve and speed up the diagnostics and therapy of the
      malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      In this observational study the investigators aim to evaluate whether optical spectroscopy
      can correctly diagnose malignant tissue in the existing clinical workflow of percutaneous
      interventions in lung, liver, and breast.

      Secondary Objective:

      During the measurement procedure, possible improvements of the measurement hardware will be
      recorded. Analysis of this documentation will provide information for possible alterations
      of hardware design for improved clinical applicability in the future. Special attention will
      be paid to observe how the procedure fits in the standard workflow of the radiologist.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Differentiation between normal and malignant tissue</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Statistical analysis of the difference between diffuse reflectance spectra obtained at normal and malignant measurement locations</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Pulmonary Coin Lesion</condition>
  <condition>Colon Cancer Liver Metastasis</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Histological biopsy procedures</arm_group_label>
    <description>Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Core biopsy procedure</intervention_name>
    <description>Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.</description>
    <arm_group_label>Histological biopsy procedures</arm_group_label>
    <other_name>Histological biopsy procedure</other_name>
    <other_name>Standard biopsy procedure</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsies are taken from the enrolled patients and these biopsies are send to the pathology
      department for histopathological analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients are all patients, who are scheduled for a standard core biopsy of lung,
        liver or breast; or percutaneous RFA of liver in the Netherlands Cancer Institute
        (NKI-AvL), Amsterdam, The Netherlands. In the enrollment process the &quot;patient informatie&quot;
        will be used and the informed consent must be signed prior to the intervention.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a suspicious lesion in lung or liver who are scheduled for a standard
             core biopsy procedure

          -  Patient planned for percutaneous RFA of colorectal liver metastasis

          -  Written informed consent

          -  Patients â‰¥ 18 years old

          -  Breast patients with a BIRADS score 4 or 5

        General Exclusion criteria:

          -  Patients who have higher risk of bleeding

          -  Patients with suspected sensitivity to light; e.g. patients who have had photodynamic
             therapy

        Breast Specific Exclusion criteria:

          -  Patients who have a history of breast cancer and/or who have received prior
             chemotherapy, endocrine therapy, or radiation therapy

          -  Patients who have breast implants

          -  Patients needing a stereotactic breast biopsy (i.e. non palpable-, ultrasound opaque
             lesions)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo Ruers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nederlands Kanker Instituut/Antonie van leeuwenhoek Ziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theo Ruers, MD</last_name>
    <phone>+31 020 5152565</phone>
    <email>t.ruers@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jarich Spliethoff, MSc</last_name>
    <phone>+31 020 5127491</phone>
    <email>j.spliethoff@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut/Antonie van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarich Spliethoff, MSc</last_name>
      <phone>+31 020 5127491</phone>
      <email>j.spliethoff@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Warner Prevoo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jarich Spliethoff, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>October 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spectroscopy</keyword>
  <keyword>tumour</keyword>
  <keyword>biopsy</keyword>
  <keyword>malignancy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Solitary Pulmonary Nodule</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
